5 High Dividend Stocks Picked By Billionaire Ray Dalio

Page 5 of 5

1. Johnson & Johnson (NYSE:JNJ)

Bridgewater Associates’ Stake Value as of Q4 2025: $271,923,608

Dividend Yield as of April 17: 2.29%

On April 15, Bank of America raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $254 from $253. It kept a Neutral rating on the shares. The firm described the quarter as “an okay 1Q print” that “offered nothing thesis changing.”

During the Q1 2026 earnings call, CFO Joseph Wolk said the company raised its operational sales outlook to a range of 5.9% to 6.9%, with a midpoint of $100.2 billion. He added that reported sales are now expected to grow between 6.5% and 7.5%, implying a midpoint of $100.8 billion. He also said earnings guidance was lifted by $0.02, bringing the expected range to $11.30 to $11.50.

At the same time, the company maintained its view that the adjusted pretax operating margin will improve by at least 50 basis points in 2026. He noted that a larger share of investments will be weighted toward the first half of the year. Compared with the initial 2026 outlook shared in Q4, he pointed out a shift in tone. Management moved from saying they “anticipated” growth to indicating they are actively increasing both sales growth and adjusted EPS guidance ranges.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company that operates across the healthcare sector through its Innovative Medicine and MedTech segments.

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: Top 10 Reddit Stocks That Will Skyrocket and 10 Fastest Growing Dividend Stocks to Buy Now

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5